Medical Devices Reimbursement Market

Medical Devices Reimbursement Market Summary:

As per Transpire Insight Analysis, the Medical Devices Reimbursement Market size is estimated at USD 620.1 billion in 2025 and is anticipated to reach USD 1020.3 billion by 2033, growing at a CAGR of 6.43% from 2026 to 2033. The growth of the market is driven by digitisation in the process of insurance reimbursement, value-based care, faster claim processing, and cost-effectiveness.

The global reimbursement of medical devices market is increasingly being integrated into the process of managing costs associated with the use of diagnostic, therapeutic, surgical, and monitoring devices by healthcare providers, payers, and end-users.

There have been many changes regarding reimbursement policies during recent years. It is currently done in a digital fashion that assists in managing expenses and ensures that the treatment is provided correctly. One of the major changes that has occurred is that reimbursements are now made according to the outcome of the treatment. Such a reimbursement is named value-based.

Various tools are applied to simplify the process of approval of the treatments and the claims. In the U.S., such changes include the creation of the rules for obtaining permission for treatment by the Centres for Medicare and Medicaid Services (CMS). Such changes will assist patients in obtaining the necessary devices while avoiding paying for those that are not needed by the insurance companies. Consequently, the use of medical devices will become widespread because of the improvement of the reimbursement policy and its orientation towards the outcomes of the medical devices.

Medical Devices Reimbursement Market Size & Forecast:

• Global Market Size 2025: USD 620.1 Billion
• Expected Market Value (2033): USD 1020.3 Billion
• Forecast CAGR (2026–2033): 6.43%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific
• Key Company Profiles: UnitedHealth Group, Elevance Health, CVS Health (Aetna), Cigna Healthcare, Humana, Kaiser Permanente, Medtronic, Abbott, Boston Scientific, Johnson & Johnson MedTech, Siemens Healthineers, GE HealthCare, Philips Healthcare, Zimmer Biomet, Stryker

Key Market Insights:

There is a move towards reimbursement methods that will provide better access to medical devices while keeping costs under control at the same time. Government insurance will continue to play an important role in financing but will be overshadowed by value-based reimbursement systems.

• Public Health Insurance is the leading reimbursement model, occupying a 39% share of the market. This emphasises the significance of governmental health insurance for medical devices introduction.
• Private Health Insurance occupies 25% of the market and is driven by insurers’ efforts to introduce new coverage programs and to use digital claims systems to streamline the process.
• Medicare/Medicaid occupies 16% of the market and shows the persistent popularity of government health care programs in supporting access to medical devices.
• The Value-Based Reimbursement Model is the fastest-growing segment with 12.8% CAGR. This reflects the trend when healthcare providers link payments to treatment outcomes.
• Diagnostic Devices occupy a 6% share of the market, driven by rising use of diagnostic technologies requiring reimbursement.
• Other models take 3% of the market, showing a certain persistence of other reimbursement approaches.
• Healthcare companies are increasingly adopting digital solutions for claims, authorisations, and payments to speed up reimbursement processes.

What are the Key Drivers, Restraints, and Opportunities in the Medical Devices Reimbursement Market?

Drivers

Growth in the global medical device reimbursement market will be driven by the adoption of result-oriented reimbursement models and the increasing use of digital reimbursement solutions. Automation of claims and approval processes is used by healthcare providers and payers to minimise administrative inefficiencies, and value-based reimbursement continues to grow. The transition to this model can enhance the adoption of medical devices by streamlining the payment process.

Restraints

barrier would be the complexity of reimbursement systems in different health systems. There are usually variations in eligibility, documentation, and payments that vary among insurers, government payers, and providers, thus making it challenging for manufacturers to devise an effective reimbursement strategy. Another potential barrier could be the difficulty in measuring outcomes.

Opportunities

 Opportunities will be in the development of digital and value-based reimbursement models. More funding in the areas of claims processing, data analysis, and monitoring of outcomes may allow insurers to better determine the efficacy of devices. There is also room for growth in the Asia Pacific region, where growth is forecasted.

What Has the Impact of Artificial Intelligence Been on the Medical Devices Reimbursement Market?

The use of artificial intelligence is facilitating the speed and efficiency of reimbursement procedures through automating the processing of large numbers of claims and patient data by insurance companies and healthcare organisations. AI-powered software can automate claims review, determine missing documents, and facilitate faster decision-making on claims. Predictive analytics technology can help payers spot strange trends in claims, estimate the cost of medical device reimbursement, and predict its effect on the overall costs of operations. The described capabilities may help to lower the amount of manual work required from insurers and healthcare organisations. AI technology may also be used for outcome-based reimbursement analysis through treatment data collection and comparison of the performance of devices with the health status of patients. The introduction of digital technologies into reimbursement processes will enable greater integration among manufacturers, providers, and insurance companies. However, the implementation of such technologies faces difficulties due to high costs, the need for integration with healthcare platforms, and the necessity of accurate data.

Instance

In March 2026, UnitedHealth Group incorporated the application of AI in health care administration and reimbursement operations such as claims and payments management. AI is being applied by the firm to decrease administrative tasks, increase efficiency in payments, and make reimbursement decisions accurately. This demonstrates how AI is facilitating medical devices and health care reimbursements faster and more efficiently.

https://www.reuters.com/legal/litigation/us-insurers-hospitals-turn-new-ai-age-old-battle-over-charges-vs-payments-2026-03-12/

Key Market Trends

There is a shift from traditional reimbursement models to more efficient, digital, and results-oriented ones. The insurance companies and the healthcare sector are increasingly applying technological methods to simplify claim processes, make payments, and control device-specific healthcare expenses.

• There is an increased usage of digital processing of reimbursements, which replaces manually conducted claims and authorisations with the use of technology.
• The value-based reimbursement model is growing popular, where the payments are increasingly determined based on results rather than volume of services provided.
• The prior authorisation process is more technology-oriented, thus allowing healthcare organisations to decrease delays in processing and workload.
• Data analysis plays a significant role in allowing the payers to effectively evaluate device usage, cost of treatments, and reimbursement trends.
• Results monitoring is increasingly relevant, urging providers to prove the effectiveness of the medical devices they utilise.
• Providers desire shorter reimbursement periods, hence the increased need for technological solutions.

Medical Devices Reimbursement Market Segmentation

By Payer Type

Public Health Insurance dominates with 39% of the market, followed by Private Health Insurance with 25% and Medicare/Medicaid with 16%. Public health insurance will continue to be vital to the process of device reimbursement due to its role in ensuring accessibility for a large number of people, whereas private health insurance continues to develop schemes for paying for the devices.

By Device Type

 Diagnostic devices represent 6% of the market. The rest of the devices are divided into such groups as therapeutic, implantable, monitoring and surgical devices. Requirements for reimbursement vary depending on clinical application, treatment value and cost of the device. Future strategies for reimbursement will put more emphasis on the results that can be achieved with the use of the devices.

By End User

 Hospitals, clinics, ambulatory surgical centres, home healthcare facilities, and diagnostic centres are considered to be the reimbursement channels. Hospitals have particular significance because they are using various medical devices that require reimbursement. Emergence of trends related to decentralized/home-based care may bring new reimbursement requirements in addition to the traditional ones.

By Application

Cardiology, orthopaedics, neurology, diabetes management, and oncology are some of the applications that indicate that reimbursement affects the availability of medical devices. 6% is attributed to Diagnostic Devices, also indicating the significance of reimbursement of diagnostic procedures in these applications. As treatment continues to become more specialised, there will be a shift towards value-based reimbursement decisions.

By Reimbursement Models

 Value-Based Reimbursement is the fastest growing, with a CAGR of 12.8%, while accounting for 11% of the provided segment mix. Fee-for-service, bundled payments, and capitation are still relevant, although outcome-based models are beginning to attract some attention since they link payment of health care with results.

What are the Key Use Cases Driving the Medical Devices Reimbursement Market?

Health insurance for the general public is one of the areas of application of the process of reimbursement for medical devices. It assists in handling expenses associated with the costs of diagnostic, therapeutic, surgical, and monitoring tools for health institutions. Reimbursement ensures that patients have access to such devices without the total burden falling on the individual patients. Other applications for reimbursement include various devices used in the fields of cardiology, orthopaedics, neurology, diabetes care, and oncology. As health institutions incorporate devices in their treatment procedures, more institutions are incorporating reimbursement in their operations.

New applications are tied to the issue of value-based reimbursement. In such a system, reimbursement is increasingly being tied to the quality of treatment offered to patients. Such an arrangement enables health providers to choose effective and economical devices while offering chances for manufacturers to assist in reimbursement decisions based on outcomes.

Which Regions are Driving the Medical Devices Reimbursement Market Growth?

North America

The North American region dominates the Medical Devices Reimbursement Market with a market share of 48%. This dominance can be attributed to factors such as the presence of robust healthcare facilities, a mature insurance system, and wide reach of advanced medical technologies in the region.In April 2026, CMS and FDA introduced the Regulatory Alignment for Predictive and Immediate Device (RAPID) Coverage Pathway to expedite the Medicare coverage process for selected FDA-designated Breakthrough Devices. Under this new pathway, CMS will be able to start the coverage process once the FDA approves the device, resulting in Medicare coverage within 60-90 days. This will enhance reimbursement predictability for device innovators such as Medtronic and Johnson & Johnson.

Europe

Europe market size is 28%. Well-established public healthcare systems and reimbursement systems are some of the key strengths of Europe. As compared to the North American region, this region emphasises healthcare coverage and cost management. These reimbursement systems not only provide stability for device reimbursement but also provide continued access to medical technologies.In February 2025, the French Government declared that starting December 2025, France would reimburse wheelchairs completely under the public health insurance. It applies to all standard wheelchairs that are included in the national system and some specialised wheelchairs after a medical approval. This will help to lower costs and ease the reimbursement process for medical equipment.

Asia Pacific

The Asia Pacific region occupies 18% of the market share and is growing at the highest rate with a CAGR of 13.5%. Growth in healthcare facilities, insurance systems, and adoption of medical technologies is improving the opportunities for reimbursement. Developing healthcare systems in this region will create new opportunities for the reimbursement of medical devices. In August 2025, the Ministry of Health, Labour and Welfare (MHLW) of Japan included the Accurian Pain Management Radiofrequency System of Medtronic Japan into the list of the Japanese National Health Insurance reimbursement program. The insurance coverage will start on September 1, 2025.

Who are the Key Players in the Medical Devices Reimbursement Marketand how do they Compete?

The worldwide medical devices reimbursement market is competitive, with the participation of healthcare insurers, reimbursement services providers, technology players, and medical devices manufacturers striving for better coverage, claim processing, and payment management. Competitive pressures become more focused on the availability of digital solutions, fast authorisation, cost control and demonstration of the value of medical technologies.

Key players implement competitive strategies in various ways. Digital solutions strategy implies automation and integration of systems along with the use of analytics to streamline the process and enhance decision-making. The strategy of cost efficiency involves providing healthcare organisations with efficient solutions to deal with claims and administrative costs. A niche strategy allows reimbursement companies to develop reimbursement solutions for specific types of devices or healthcare organisations.

Strategic development and expansion is another popular competitive approach. The players intensify their collaboration with insurers, healthcare providers and technology companies to expand their presence and develop better reimbursement networks. The companies, which have effective processing combined with good data and outcome-based reimbursement capabilities, are likely to be more popular among healthcare organisations due to the trend of payment system transformation.

Medical Devices Reimbursement Market companies

• UnitedHealth Group
• Elevance Health
• CVS Health (Aetna)
• Cigna Healthcare
• Humana
• Kaiser Permanente
• Medtronic
• Abbott
• Boston Scientific
• Johnson & Johnson MedTech
• Siemens Healthineers
• GE HealthCare
• Philips Healthcare
• Zimmer Biomet
• Stryker

Recent Development News

In December 2025, the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot program was introduced by the U.S. Food & Drug Administration (FDA). The program was aimed at facilitating access to certain digital health devices through collecting data about patient outcomes that would establish a closer link between medical device innovations and reimbursement.

https://www.fda.gov

In May 2026, CMS amended requirements for the payment and coding for non-invasive bone growth stimulators due to their FDA reclassification from Class III to Class II medical devices. It affected the coding and Medicare fee schedule payments for applicable HCPCS codes.

https://www.cms.gov

What Strategic Insights Define the Future of the Medical Devices Reimbursement Market?

The medical devices reimbursement market worldwide will become more flexible, technology-driven, and result-oriented in the future. The importance of quantifiable outcomes, cost efficiency, and real-world evidence in reimbursement for technologies will increase for both payers and healthcare organisations. An implicit threat will be the complexity of reimbursement policies within healthcare systems, which leads to inconsistencies in reimbursement decisions and delays the market entry of manufacturers. Moreover, integration difficulties with old systems of insurance and healthcare will be another obstacle for the implementation of innovations in reimbursement. New opportunities will consist of the application of artificial intelligence and data analytics along with value-based reimbursement for assessing the results of the operation of medical devices. Manufacturers need to pay attention to generating evidence, partnership development with payers and healthcare providers, and designing reimbursement strategies from an early stage of product development.

By Payer Type

• Public Health Insurance
• Private Health Insurance
• Medicare/Medicaid
• Employer-sponsored Insurance
• Out-of-pocket

By Device Type

• Diagnostic Devices
• Therapeutic Devices
• Implantable Devices
• Monitoring Devices
• Surgical Devices

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centres
• Home Healthcare
• Diagnostic Centres

By Application

• Cardiology
• Orthopedics
• Neurology
• Diabetes Care
• Oncology

By Reimbursement Model

• Fee-for-Service
• Value-Based Reimbursement
• Bundled Payments
• Capitation

Regional Outlook

North America

• US 
• Canada 
• Mexico 

Europe

• Germany 
• UK 
• France 
• Italy 
• Spain 
• Russia 
• Rest of Europe 

Asia Pacific

• China 
• Japan 
• India 
• South Korea 
• Australia 
• Rest of Asia Pacific 

South America

• Brazil 
• Argentina 
• Rest of South America 

Middle East & Africa

• UAE 
• Saudi Arabia 
• Qatar 
• South Africa 
• Rest of the Middle East & Africa